Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRI 724

Drug Profile

PRI 724

Alternative Names: ICG-001; OP-724; PRI-724

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer Ohara Pharmaceutical; PRISM Pharma Co; Syneos Health; Tokyo Metropolitan Komagome Hospital
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Primary biliary cirrhosis
  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Hepatic fibrosis; Pancreatic cancer; Solid tumours

Most Recent Events

  • 29 Aug 2019 Phase-I clinical trials in Primary biliary cirrhosis in Japan (IV) (NCT04047160)
  • 06 Aug 2019 Ohara Pharmaceutical and Japan Agency for Medical Research and Development plan a phase I trial in Primary biliary cirrhosis in August 2019 (IV) (NCT04047160)
  • 29 Aug 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top